Agenus to Participate at Upcoming Investor Conferences
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced its participation in two investor conferences. The H.C. Wainwright Bioconnect Conference will feature an on-demand presentation starting January 10, 2022. Additionally, they will present at the B. Riley Securities’ 2022 Virtual Oncology Conference on January 27, 2022, at 1:00 PM EST. Investors can access webcasts and replays on the company's website. Agenus focuses on developing therapies that utilize the immune system to combat cancer and has a robust pipeline of treatments.
- None.
- None.
LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will participate in the following upcoming investor conferences:
- H.C. Wainwright Bioconnect Conference – presentation will be available on-demand from Monday, January 10, 2022 from 7:00 AM EST
- B. Riley Securities’ 2022 Virtual Oncology Conference – presentation will be on Thursday, January 27, 2022 at 1:00 PM EST
A webcast/replay for the conferences may be accessed on the company's website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Agenus Inc.
Divya Vasudevan, PhD
781-674-4571
divya.vasudevan@agenusbio.com
Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
What investor conferences will Agenus participate in January 2022?
At what time will Agenus present at the B. Riley Securities oncology conference?
How can investors access Agenus' conference presentations?
What is the focus of Agenus as a company?
What is the stock symbol for Agenus?
